Actualités et vidéos - REGULUS THERAPEUTICS INC.

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire SAN DIEGO, March 21, 2024 Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Oversubscribed $100 million private placement; expected to extend cash runway into H1 2026 Completed enrollment of the third cohort of patients in the MAD study;...

Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew? PR Newswire NEW YORK, March 12, 2024 NEW YORK , March 12, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBAI, NUKK, SGLY, RGLS, and RERE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BBAI:...

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity PR Newswire SAN DIEGO, March 12, 2024 SAN DIEGO , March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional...

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, March 12, 2024 Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the...

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Jan. 2, 2024 SAN DIEGO , Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire SAN DIEGO, Nov. 22, 2023 SAN DIEGO , Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday November...

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates PR Newswire SAN DIEGO, Nov. 9, 2023 Announced positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed enrollment in the second cohort of the Phase 1b MAD Clinical Trial of RGLS8429 for the Treatment of ADPKD First patient dosed in the third cohort of the Phase...

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Nov. 2, 2023 SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing...

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Oct. 19, 2023 SAN DIEGO , Oct. 19, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available...

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Sept. 20, 2023 Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients with ADPKD Company to hold...

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Sept. 13, 2023 SAN DIEGO , Sept. 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"),...

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire SAN DIEGO, Sept. 5, 2023 SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C....

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 PR Newswire SAN DIEGO, Aug. 23, 2023 SAN DIEGO , Aug. 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will host a virtual investor event on Wednesday, September 6, 2023 , focused on its lead program, RGLS8429, a novel therapy in clinical...

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates PR Newswire SAN DIEGO, Aug. 8, 2023 First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 R&D Day to discuss our ADPKD program to be held Wednesday, September 6 th Strengthened leadership through appointments of Preston S. Klassen , M.D. as President and Head of Research & Development and Curtis A....

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire SAN DIEGO, Aug. 2, 2023 SAN DIEGO , Aug. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be presenting at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 , at 11:30...

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference PR Newswire SAN DIEGO, July 18, 2023 SAN DIEGO , July 18, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Dr. Preston Klassen , President and Head of Research & Development of Regulus, will present at the H.C. Wainwright 2nd Annual...

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, June 27, 2023 SAN DIEGO , June 27, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the...

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors PR Newswire SAN DIEGO, June 23, 2023 SAN DIEGO , June 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced Preston S. Klassen , M.D., President and Head of Research & Development, has been appointed to the Company's Board of...

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital PR Newswire SAN DIEGO, June 20, 2023 Program advances to lead compound evaluation in preclinical in vivo models Preliminary data for in vivo studies are expected in second half of 2023 SAN DIEGO , June 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and...

Regulus Therapeutics Strengthens Research & Development Leadership PR Newswire SAN DIEGO, June 12, 2023 Appoints Preston S. Klassen, M.D., as President and Head of Research & Development Curtis A. Monnig, Ph.D., named Vice President of CMC SAN DIEGO , June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment...